ROCHE HOLDINGS AG (RHHBY)

36.56
0.82 2.29
OTC
Prev Close 35.74
Open 36.32
Day Low/High 36.19 / 36.58
52 Wk Low/High 25.10 / 36.56
Volume 1.66M
Exchange OTC
Shares Outstanding 702.56B
Market Cap 195.59B
Div & Yield N.A. (N.A)

Latest News

Phase III PEMPHIX Study Shows Genentech's Rituxan (rituximab) Superior To Mycophenolate Mofetil In Patients With Pemphigus Vulgaris

Phase III PEMPHIX Study Shows Genentech's Rituxan (rituximab) Superior To Mycophenolate Mofetil In Patients With Pemphigus Vulgaris

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced data from the Phase III PEMPHIX study evaluating the efficacy and safety of Rituxan ® (rituximab) compared to mycophenolate mofetil (MMF), in adults with moderate to...

Amgen Downgraded, AbbVie Added to Bullpen

We see fewer pathways and catalysts that will get AMGN stock higher, and are downgrading our rating to a THREE, looking to sell into strength.

Genentech Presents Positive Phase III Results For Tecentriq (Atezolizumab) In Combination With Platinum-based Chemotherapy In People With Previously Untreated Advanced Bladder Cancer

Genentech Presents Positive Phase III Results For Tecentriq (Atezolizumab) In Combination With Platinum-based Chemotherapy In People With Previously Untreated Advanced Bladder Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today presented positive results from the Phase III IMvigor130 study evaluating Tecentriq ® (atezolizumab) plus platinum-based chemotherapy versus chemotherapy alone for the first-line...

Genentech To Present Results Of First Prospective Trial Using Blood-based Next Generation Sequencing Which Successfully Identifies People For Treatment With Alecensa (Alectinib)

Genentech To Present Results Of First Prospective Trial Using Blood-based Next Generation Sequencing Which Successfully Identifies People For Treatment With Alecensa (Alectinib)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will today announce positive results from a single-arm cohort of the Phase II/III Blood First Assay Screening Trial (BFAST), the first prospective study to use only blood-based next...

FDA Approves Genentech's Rituxan (rituximab) In Children With Two Rare Blood Vessel Disorders

FDA Approves Genentech's Rituxan (rituximab) In Children With Two Rare Blood Vessel Disorders

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

FDA Grants Breakthrough Therapy Designation For Genentech's Gazyva (Obinutuzumab) In Lupus Nephritis

FDA Grants Breakthrough Therapy Designation For Genentech's Gazyva (Obinutuzumab) In Lupus Nephritis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Genentech Presents New Six-year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation And Continuation Of Treatment Reduced Disability Progression In Multiple Sclerosis

Genentech Presents New Six-year Ocrevus (Ocrelizumab) Data Which Showed That Earlier Initiation And Continuation Of Treatment Reduced Disability Progression In Multiple Sclerosis

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today longer-term data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO showed that patients who were treated with Ocrevus ® (ocrelizumab)...

Genentech's Fixed Dose Subcutaneous Combination Of Perjeta And Herceptin Showed Non-Inferiority When Compared To Intravenous Formulations For People With HER2-Positive Breast Cancer

Genentech's Fixed Dose Subcutaneous Combination Of Perjeta And Herceptin Showed Non-Inferiority When Compared To Intravenous Formulations For People With HER2-Positive Breast Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the Phase III FeDeriCa study met its primary endpoint.

Genentech's Satralizumab Significantly Reduced Relapse Risk In Second Positive Phase III Study For Neuromyelitis Optica Spectrum Disorder

Genentech's Satralizumab Significantly Reduced Relapse Risk In Second Positive Phase III Study For Neuromyelitis Optica Spectrum Disorder

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today full pivotal Phase III study results for satralizumab as a monotherapy for neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating central nervous system...

Genentech's Tecentriq (Atezolizumab) As A First-Line Monotherapy Helped Certain People With Advanced Non-Small Cell Lung Cancer Live Longer Compared With Chemotherapy

Genentech's Tecentriq (Atezolizumab) As A First-Line Monotherapy Helped Certain People With Advanced Non-Small Cell Lung Cancer Live Longer Compared With Chemotherapy

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive data from the Phase III IMpower110 study evaluating Tecentriq ® (atezolizumab) as a first-line (initial) monotherapy compared with cisplatin or carboplatin and...

Genentech Presents New Ocrevus (Ocrelizumab) Biomarker Data That Increase Understanding Of Disease Progression In Multiple Sclerosis At ECTRIMS

Genentech Presents New Ocrevus (Ocrelizumab) Biomarker Data That Increase Understanding Of Disease Progression In Multiple Sclerosis At ECTRIMS

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new data from Ocrevus ® (ocrelizumab) trials in relapsing and primary progressive multiple sclerosis (MS).

For Wealth and Safety Invest With a 'Shark'

For Wealth and Safety Invest With a 'Shark'

Four ETFs designed around Kevin O'Leary's growth, income and wealth preservation-oriented strategy.

Catalyst Events to Watch in Amgen and Novartis Pipelines

The pipeline is key for pharmaceutical companies.

Genentech To Present Pivotal Data For Satralizumab In Neuromyelitis Optica Spectrum Disorder And Six-year Ocrevus (Ocrelizumab) Data In Multiple Sclerosis At ECTRIMS

Genentech To Present Pivotal Data For Satralizumab In Neuromyelitis Optica Spectrum Disorder And Six-year Ocrevus (Ocrelizumab) Data In Multiple Sclerosis At ECTRIMS

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data across its neuroscience portfolio will be presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis...

The Top 25 Wealthiest Families in the World

The Top 25 Wealthiest Families in the World

These families have built their wealth in everything from retail to fine chocolates.

Positive Phase III Results Show Xofluza (Baloxavir Marboxil) Reduces Risk Of Developing The Flu After Contact With An Infected Person By 86 Percent

Positive Phase III Results Show Xofluza (Baloxavir Marboxil) Reduces Risk Of Developing The Flu After Contact With An Infected Person By 86 Percent

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III BLOCKSTONE study showed preventive treatment with Xofluza™ (baloxavir marboxil) after exposure to an infected household member significantly reduced...

Genentech Presents Positive Phase III Study Results For One-dose Xofluza (Baloxavir Marboxil) In Children With The Flu

Genentech Presents Positive Phase III Study Results For One-dose Xofluza (Baloxavir Marboxil) In Children With The Flu

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III MINISTONE-2 study showed that one-dose Xofluza ™ (baloxavir marboxil) was a well-tolerated and effective potential treatment for the flu in otherwise...

FDA Approves Genentech's Rozlytrek (entrectinib) For People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer And NTRK Gene Fusion-Positive Solid Tumors

FDA Approves Genentech's Rozlytrek (entrectinib) For People With ROS1-Positive, Metastatic Non-Small Cell Lung Cancer And NTRK Gene Fusion-Positive Solid Tumors

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Roche To Showcase How Health Networks Are Driving Change Through Innovation In The Lab And Beyond At AACC 2019 Clinical Lab Expo

Roche To Showcase How Health Networks Are Driving Change Through Innovation In The Lab And Beyond At AACC 2019 Clinical Lab Expo

- Featured health networks improve patient care through innovative technologies and optimizing operations

Genentech's Tecentriq® (ATEZOLIZUMAB) Plus Platinum-based Chemotherapy Reduced The Risk Of Disease Worsening Or Death In People With Previously Untreated Advanced Bladder Cancer

Genentech's Tecentriq® (ATEZOLIZUMAB) Plus Platinum-based Chemotherapy Reduced The Risk Of Disease Worsening Or Death In People With Previously Untreated Advanced Bladder Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMvigor130 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS).

AstraZeneca Outlines Drug Pipeline, Partnerships, Pricing Impacts

AstraZeneca Outlines Drug Pipeline, Partnerships, Pricing Impacts

Here's what you need to know if AstraZeneca's pipeline could affect your portfolio.

Genentech Presents A Broad Range Of Data For Hemlibra (Emicizumab-kxwh) Demonstrating Continued Benefits For People With Hemophilia A At The ISTH 2019 Congress

Genentech Presents A Broad Range Of Data For Hemlibra (Emicizumab-kxwh) Demonstrating Continued Benefits For People With Hemophilia A At The ISTH 2019 Congress

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new data for Hemlibra ® (emicizumab-kxwh) across multiple pivotal studies in people with hemophilia A with and without factor VIII inhibitors at the International Society...

Genentech Announces Positive Results For First Global Phase III Study Investigating One-dose XOFLUZA (Baloxavir Marboxil) In Children With The Flu

Genentech Announces Positive Results For First Global Phase III Study Investigating One-dose XOFLUZA (Baloxavir Marboxil) In Children With The Flu

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III MINISTONE-2 study met its primary endpoint, demonstrating that XOFLUZA™ (baloxavir marboxil) was well-tolerated in children with the flu.

Biogen Drops After Piper Jaffray Downgrade, Price Target Cut

Biogen Drops After Piper Jaffray Downgrade, Price Target Cut

The firm now has a neutral rating on Biogen based on data from a new neurologist survey.

Phase III PEMPHIX Study Showed That Genentech's Rituxan (Rituximab) Is Superior To Standard Of Care In Achieving Sustained Remission In Patients With Pemphigus Vulgaris

Phase III PEMPHIX Study Showed That Genentech's Rituxan (Rituximab) Is Superior To Standard Of Care In Achieving Sustained Remission In Patients With Pemphigus Vulgaris

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive top line results from the Roche-sponsored Phase III PEMPHIX study evaluating the efficacy and safety of Rituxan ® (rituximab) compared to mycophenolate mofetil...

FDA Grants Priority Review To Genentech's Rituxan (Rituximab) In Children With Two Rare Blood Vessel Disorders

FDA Grants Priority Review To Genentech's Rituxan (Rituximab) In Children With Two Rare Blood Vessel Disorders

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Genentech's Gazyva (Obinutuzumab) Delivers Positive Topline Results For Phase II Lupus Nephritis Study

Genentech's Gazyva (Obinutuzumab) Delivers Positive Topline Results For Phase II Lupus Nephritis Study

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive topline results for NOBILITY, a Phase II clinical trial investigating the safety and efficacy of Gazyva ® (obinutuzumab) for adults with proliferative lupus...

FDA Grants Genentech's Polivy Accelerated Approval For People With Previously Treated Aggressive Lymphoma

FDA Grants Genentech's Polivy Accelerated Approval For People With Previously Treated Aggressive Lymphoma

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.